Levetiracetam Patent Expiration
Levetiracetam was first introduced by Ucb Inc
Levetiracetam Patents
Given below is the list of patents protecting Levetiracetam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Spritam | US11160786 | Rapid disperse dosage form | Mar 14, 2034 | Aprecia Pharms |
| Spritam | US9339489 | Rapid disperse dosage form containing levetiracetam | Mar 14, 2034 | Aprecia Pharms |
| Spritam | US9669009 | Rapid disperse dosage form containing levetiracetam | Mar 14, 2034 | Aprecia Pharms |
| Keppra |
US8802142 (Pediatric) | Pharmaceutical compositions comprising levetiracetam and process for their preparation | Dec 07, 2031 | Ucb Inc |
| Keppra | US8802142 | Pharmaceutical compositions comprising levetiracetam and process for their preparation | Jun 07, 2031 | Ucb Inc |
| Keppra Xr | US7858122 | Extended release formulation of levetiracetam | Sep 17, 2028 | Ucb Inc |
| Elepsia Xr | US8431156 | Pharmaceutical composition | Oct 31, 2027 | Tripoint |
| Elepsia Xr | US8470367 | Oral drug delivery system | Oct 31, 2027 | Tripoint |
| Elepsia Xr | US8163306 | Oral drug delivery system | Sep 03, 2027 | Tripoint |
| Elepsia Xr | US8425938 | Pharmaceutical composition |
Feb 22, 2026
(Expired) | Tripoint |
| Elepsia Xr | US8535717 | Pharmaceutical composition |
Feb 22, 2026
(Expired) | Tripoint |
| Spritam | US6471992 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
Feb 20, 2018
(Expired) | Aprecia Pharms |
| Spritam | US9463160 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
Feb 20, 2018
(Expired) | Aprecia Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Levetiracetam's patents.
Latest Legal Activities on Levetiracetam's Patents
Given below is the list recent legal activities going on the following patents of Levetiracetam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 16 Jan, 2025 | US11160786 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 03 Dec, 2024 | US9669009 |
| Post Issue Communication - Certificate of Correction | 26 Jan, 2022 | US11160786 |
| Recordation of Patent Grant Mailed Critical
| 02 Nov, 2021 | US11160786 |
| Patent Issue Date Used in PTA Calculation Critical
| 02 Nov, 2021 | US11160786 |
| Email Notification Critical
| 14 Oct, 2021 | US11160786 |
| Issue Notification Mailed Critical
| 13 Oct, 2021 | US11160786 |
| Application Is Considered Ready for Issue Critical
| 01 Oct, 2021 | US11160786 |
| Dispatch to FDC | 01 Oct, 2021 | US11160786 |
| Issue Fee Payment Verified Critical
| 28 Sep, 2021 | US11160786 |
Levetiracetam's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Levetiracetam:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
